Author Index for Volume 30

Abe K. *See* Terao T
Adler NT. *See* Stewart KT
Akiyama K. *See* Fujisawa Y
Albert K. *See* Bartels M
Alexander RC, Illowsky Karp B, Thompson S, Khot V, Kirch DG. A double blind, placebo-controlled trial of demeclocycline treatment of polydipsia-hyponatremia in chronically psychotic patients, 417
Al-Shabbout M. *See* Dahl RE
Altmann J. *See* Sapolsky RM
Anderson IM, Cowen PJ. Prolactin response to the dopamine antagonist, metoclopramide, in depression, 313
Andrews S. *See* Shelley AM
Andrien M. *See* Staner L
Angrist B. *See* Nemes Z
Ansseau M. *See* Wauthy J
Aprison MH. *See* Engleman EA
Arora RC. *See* Bastani B
ÅsbergM. *See* Bartfai A
Asnis GM. *See* Iqbal N
Auclair M. *See* Lejoyeux M
Austin LS, Lydiard RB, Ballenger JC, Cohen BM, Laraia MT, Zealberg JJ, Fossey MD, Ellinwood EH. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder, 225
Avery DH. *See* Cowley DS

Bachneff SA. Positron emission tomography and magnetic resonance imaging: a review and a local circuit neurons hypo(dys)function hypothesis of schizophrenia, 857
Bäckström T. *See* Näsman B
Ballard L. *See* Hoffman WF
Ballenger JC. *See* Austin LS
Ballenger JC. *See* Brady KT
Barkai AI, Prohovnik I, Young WL, Durkin M, Nelson HD. Alterations of local cerebral blood flow and glucose uptake by electroconvulsive therapy, 269
Bartels M, Günther U, Albert K, Mann K, Schuff N, Stuckstedte H. ^{19}F nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain, 656
Bartfai A, ÅsbergM, Mårtensson B, Gustavsson P. Memory effects of clomipramine treatment: relationship to CSF monoamine metabolites and drug concentrations in plasma, 1075
Baruah S. *See* Sherman AD
Baschieri P. *See* Placidi GF
Bastani B, Arora RC, Meltzer HY. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients, 131
Baxter LR Jr. *See* Szuba MP
Beats B, Levy R, Förstl H. Ventricular enlargement and caudate hyperdensity in elderly depressives, 452
Belenky G. *See* McCann UD
Benazzi F. Lorazepam, amitriptyline, and sulpiride: withdrawal effects, 528-le
Berrettini WH. Is investment in molecular genetics worthwhile?, 213-ed
Berrettini WH. *See* Sunderland T
Berrios GE. *See* Dening T
Bigelow LB. *See* Bracha HS
Bigelow LB. *See* Gold JM
Bignami G. Neuroleptic dysphoria in animals, 844-le
Blacker M. *See* Silver H
Blackshaw S. *See* Davis BA
Blackwood DHR, Young AH, McQueen JK, Martin MJ, Roxborough HM, Muir WJ, St. Clair DM, Kean DM. Magnetic resonance imaging in schizophrenia: altered brain morphology associated with P300 abnormalities and eye tracking dysfunction, 753
Bleich A. *See* Dagan Y
Born J. *See* Schreiber H
Bosmans E. *See* Maes M
Botschev C, Müller N. Opiate receptor antagonists

Abbreviations:
ed: Editorial
le: Letter to the Editor

© 1991 Society of Biological Psychiatry

0006-3223/91/$03.50

for delusions of parasitosis, 530-le
Bouillon E. *See* Staner L
Boulton AA. *See* Davis BA
Boulton AA. *See* O'Reilly R
Bowen RC. *See* Davis BA
Bowers MB. *See* Mazure CM
Bracha HS, Torrey EF, Bigelow LB, Lohr JB, Linington BB. Subtle signs of prenatal maldevelopment of the hand ectoderm in schizophrenia: a preliminary monozygotic twin study, 719
Brady KT, Lydiard RB, Ballenger JC, Shook J, Laraia M, Fossey M. CSF opioids in panic disorder, 512
Brewerton TD. Fluoxetine-induced suicidality, serotonin, and seasonality, 190
Brown GM. *See* Kennedy SH
Brown GM. *See* MacFarlane JG
Brown KW. *See* Nemes Z
Brown KW, White T. The association among negative symptoms, movement disorders, and frontal lobe psychological defects in schizophrenic patients, 1182
Bruce M, Lader M. DSM-III-R state anxiety symptoms in anxiety disorder patients, 519
Bruder GE, Towey JP, Stewart JW, Friedman D, Tenke C, Quitkin FM. Event-related potentials in depression: influence of task, stimulus hemifield and clinical features on P3 latency, 233
Bruinvels J. *See* Fekkes D
Bucht G. *See* Näsman B
Burgess JW. Neurocognition in acute and chronic depression: personality disorder, major depression, and schizophrenia, 305

Caldwell CL, Irwin M, Lohr J. Reduced natural killer cell cytotoxicity in depression but not in schizophrenia, 1131
Caligiuri MP. *See* Jeste DV
Callaway E, Halliday R, Perez-Stable EJ, Coates TJ, Hauck WW. Propranolol and response bias: an extension of findings reported by Corwin Et Al, 739
Carpenter AB. *See* Chengappa KNR
Carson SW. *See* DeVane CL
Casey DE. *See* Hoffman WF
Catalano D. *See* Placidi GF
Catts SV. *See* Shelley AM
Chamba G, Lemoine P, Flachaire E, Ferry N, Quincy C, Sassard J, Ferber C, Mocaër E, Kamoun A, Renaud B. Increased serotonin platelet uptake after tianeptine administration in depressed patients, 609
Chambers A. *See* Schiavi RC
Chase TN. *See* Heuser IJE
Chengappa KNR, Carpenter AB, Keshavan MS, Yang ZW, Kelly RH, Rabin BS, Ganguli R. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients, 731
Cleghorn JM. *See* MacFarlane JG
Clem T. *See* Hommer DW
Coates TJ. *See* Callaway E
Cody R. *See* Menza MA
Cohen BM. *See* Austin LS
Cohen RM. *See* Sunderland T
Convit A, Czobor P, Volavka J. Lateralized abnormality in the EEG of persistently violent psychiatric inpatients, 363
Cook EH Jr. *See* Perry BD
Cowen PJ. *See* Anderson IM
Cowley DS. *See* Jensen CF
Cowley DS. *See* Roy-Byrne PP
Cowley DS, Dager SR, Roy-Byrne PP, Avery DH, Dunner DL. Lactate vulnerability after alprazolam versus placebo treatment of panic disorder, 49
Csernansky JG, Murphy GM, Faustman WO. Limbic/ mesolimbic connections and the pathogenesis of schizophrenia, 383
Czobor P. *See* Convit A
Czobor P, Volavka J. Pretreatment EEG predicts short-term response to haloperidol treatment, 927

Dagan Y, Lavie P, Bleich A. Elevated awakening thresholds in sleep stage 3-4 in war-related post-traumatic stress disorder, 618
Dager SR. *See* Cowley DS
Dahl RE, Ryan ND, Puig-Antich J, Nguyen NA, Al-Shabbout M, Meyer VA, Perel J. 24-hour cortisol measures in adolescents with major depression: a controlled study, 25
Dam H. *See* Mellerup ET
Daniel DG. *See* Gold JM
Daniel DG, Goldberg TE, Gibbons RD, Weinberger DR. Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussian mixture analysis of 1056 cases and controls, 887
D'Arcy C. *See* Davis BA
Darko D. *See* Gillin JC
Davis BA. *See* O'Reilly R

Davis BA, Boulton AA, Yu PH, Durden DA, Keegan DL, Bowen RC, Blackshaw S, D'Arcy C, Remillard AJ, Dayal N, Shrikhande S, Saleh S, Stegeman GH, Paterson IA. Longitudinal effect of amitriptyline and fluoxetine treatment on plasma phenylacetic acid concentrations in depression, 600
Davis CL. *See* Molchan SE
Davis JM. *See* Kim SW
Davis JM. *See* Sharma RP
Dayal N. *See* Davis BA
De Bonis C. *See* Ferro FM
Del Carmine R. *See* Ferro FM
Del'Osso L. *See* Placidi GF
de Maertelaer V. *See* Mendlewicz J
De Meester I. *See* Maes M
Demitrack MA, Greden JF. Chronic fatigue syndrome: the need for an integrative approach, 747-ed
Dening T, Berrios GE. Alfred Hoche and the elimination of the unfit, 529-le (response)
DeRubeis RJ. *See* Garvey M
Deutsch SL. *See* Rosse RB
DeVane CL, Lim C, Carson SW, Tingle D, Hackett L, Ware MR. Effect of electroconvulsive therapy on serum concentration of alpha-1-acid glycoprotein, 116
de Wilde A. *See* van Gool WA
Dinan TG. *See* O'Flynn K
Doran AR. *See* Rapaport MH
Dubovsky SL. What we don't know about psychotic depression, 533-ed
Duchowny M. *See* Levin B
Dunner DL. *See* Cowley DS
Dupont E. *See* Staner L
Durden DA. *See* Davis BA
Durden DA. *See* O'Reilly R
Durkin M. *See* Barkai AI
Dysken MW. *See* Kim SW

Egan MF. *See* Gold JM
Ehlers CL. *See* Kupfer DJ
Eisenberg L. *See* Richmond JB
Eiser AS. *See* Taylor SF
Ellinwood EH. *See* Austin LS
Ellis WG. *See* Murphy GM Jr
Emerich DF, Sanberg PR. Neuroleptic depression in schizophrenia, 847-le (response)
Engleman EA, Hingtgen JN, Zhou FC, Murphy JM, Aprison MH. Potentiated 5-hydroxytryptophan response suppression following 5,7-dihydroxytryptamine raphe lesions in an animal model of depression, 317
Eriksson E. *See* Westberg P
Eriksson S. *See* Näsman B
Erwin RJ, Mawhinney-Hee M, Gur RC, Gur RE. Midlatency auditory evoked responses in schizophrenia, 430
Evans MD. *See* Garvey M

Fairbanks LA. *See* Szuba MP
Faustman WO. *See* Csernansky JG
Faustman WO, Moses JA Jr, Ringo DL, Newcomer JW. Left-handedness in male schizophrenic patients is associated with increased impairment on the Luria-Nebraska neuropsychological battery, 326
Fava M. *See* Otto MW
Fekkes D, Pepplinkhuizen L, Bruinvels J. Changes in serine metabolism by a serum factor present in a group of episodic psychotic patients, 966
Ferber C. *See* Chamba G
Ferro FM, Janiri L, De Bonis C, Del Carmine R, Tempesta E. Clinical outcome and psychoendocrinological findings in a case of lethal catatonia, 197
Ferry N. *See* Chamba G
Fichter M. *See* Pirke KM
Fichtner CG. *See* Harrow M
Fink M. ECT in long-term follow-up of BPD, 1172-le
Flachaire E. *See* Chamba G
Fleischhacker WW. Propanolol for fluoxetine-induced akathisia, 531-le
Forman N. *See* Menza MA
Förstl H. *See* Beats B
Fossey M. *See* Brady KT
Fossey MD. *See* Austin LS
Frank E. *See* Kupfer DJ
Freedman DX. *See* Perry BD
Friedman D. *See* Bruder GE
Friedman EH. Serum iron and akathisia, 1064-le
Friedman L, Jesberger JA, Meltzer HY. A model of smooth pursuit performance illustrates the relationship between gain, catch-up saccade rate, and catch-up saccade amplitude in normal controls and patients with schizophrenia, 537-ed
Fujisawa Y, Sasaki K, Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type, 1219

Ganguli R. *See* Chengappa KNR
Garcia-Trapero J. *See* Martin-Loeches M
Garfinkel PE. *See* Kennedy SH
Garvey M, DeRubeis RJ, Hollon SD, Evans MD, Tuason VB. Response of depression to very high plasma levels of imipramine plus desipramine, 57
Gattaz WF. *See* Pangerl AM
Gedye A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult, 88
Geraci MF. *See* Klein E
Geyer MA. *See* Keith VA
Gibbons RD. *See* Daniel DG
Gil P. *See* Martin-Loeches M
Giller EL. *See* Yehuda R
Gillin JC, Sutton L, Ruiz C, Darko D, Golshan S, Risch SC, Janowsky D. The effects of scopalamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group, 157
Gillin JC, Sutton L, Ruiz C, Golshan S, Hirsch S, Warmann C, Shiromani P. Dose dependent inhibition of REM sleep in normal volunteers by biperiden, a muscarinic antagonist, 151
Glen M. *See* Horrobin DF
Glowa JR. *See* Hoehn-Saric R
Gold JM, Egan MF, Kirch DG, Goldberg TE, Daniel DG, Bigelow LB, Wyatt RJ. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings, 587
Goldberg RL. *See* Rosse RB
Goldberg TE. *See* Daniel DG
Goldberg TE. *See* Gold JM
Golshan S. *See* Gillin JC
Goodson J. *See* Taylor SF
Gracious B, Wisner KL. Nortriptyline in chronic fatigue syndrome: a double blind, placebo-controlled single case study, 405
Grankvist K. *See* Näsman B
Graw P. *See* Kräuchi K
Greden JF. Annual meeting theme for 1992: developmental neurobiology and clinical course, 963-ed
Greden JF. *See* Demitrack MA
Greden JF. *See* Tandon R
Green MF. *See* Kern RS
Greenblatt D. *See* Roy-Byrne PP
Greenshaw AJ. *See* McManus DJ
Greil W, Steber R, van Calker D. The agonist-stimulated accumulation of inositol phosphates is attenuated in neutrophils from male patients under chronic lithium therapy, 443
Grochocinski VJ. *See* Kupfer DJ
Grossman LS. *See* Harrow M
Grossman N. *See* Menza MA
Günther U. *See* Bartels M
Gur RC. *See* Erwin RJ
Gur RE. *See* Erwin RJ
Gurguis GNM, Mefford IN, Uhde TW. Hypothalamic-pituitary-adrenocortical activity in panic disorder: relationship to plasma catecholamine metabolites, 502
Gustavsson P. *See* Bartfai A
Guze BH. *See* Szuba MP

Hackett L. *See* DeVane CL
Halliday R. *See* Callaway E
Haltiner A. *See* Hermann BP
Harrow M, Fichtner CG, Grossman LS, Yonan CA, Sands J. Neuroleptic depression in schizophrenia, 845-le
Hashimoto T. *See* Nakai T
Hauck WW. *See* Callaway E
Haug H-J. *See* Kräuchi K
Hayashi H. *See* Rosenthal L
Hegwood TS. *See* Sherman AD
Hermann BP, Seidenberg M, Haltiner A, Wyler AR. Mood state in unilateral temporal lobe epilepsy, 1205
Heuser IJE, Chase TN, Mouradian MM. The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease, 943
Hill JL. *See* Molchan SE
Hillman H. *See* Horrobin DF
Hingtgen JN. *See* Engleman EA
Hirsch S. *See* Gillin JC
Hishikawa Y. *See* Tachibana N
Hoehn-Saric R. McLeod DR, Glowa JR. The effects of NMDA receptor blockade on the acquisition of a conditioned emotional response, 170
Hoffman WF, Ballard L, Turner EH, Casey DE. Three-year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio, 913
Hollon SD. *See* Garvey M
Hommer D. *See* Roy-Byrne PP
Hommer DW, Clem T, Litman R, Pickar D. Maladaptive anticipatory saccades in schizophrenia, 779
Horrobin DF. *See* Kaiya H
Horrobin DF, Manku MS, Hillman H, Iain A, Glen

M. Fatty acid levels in the brains of schizophrenics and normal controls, 795
Howland RH, Thase ME. Biological studies of dysthymia, 283
Hsu LKG. *See* Weltzin TE
Hughes J. *See* Jensen CF

Iain A. *See* Horrobin DF
Illowsky Karp B. *See* Alexander RC
Iqbal N, Asnis GM, Wetzler S, Kahn RS, Kay SR, van Praag HM. The MCPP challenge test in schizophrenia: hormonal and behavioral responses, 770
Irwin M. *See* Caldwell CL
Iwanami A, Kato N, Nakatani Y. P300 in methamphetamine psychosis, 726

Jacobson DH. *See* Winograd CH
Janicak PG. *See* Sharma RP
Janiri L. *See* Ferro FM
Janowsky D. *See* Gillin JC
Jaroni HW. *See* Pangerl AM
Jarrett DB. *See* Wright BA
Jarvik LF. Calcium channel blocker nimodipine for primary degenerative dementia, 1171-le
Jatlow PI. *See* Mazure CM
Javaid JI. *See* Sharma RP
Jensen CF, Peskind ER, Veith RC, Hughes J, Cowley DS, Roy-Byrne P, Raskind MA. Hypertonic saline infusion induces panic in patients with panic disorder, 628
Jesberger JA. *See* Friedman L
Jeste DV, Caligiuri MP. Biological research in geriatric psychiatry, 855-ed

Kahn RS. *See* Iqbal N
Kahn RS, Wetzler S. *m*-Chlorophenylpiperazine as a probe of serotonin function, 1139
Kaiya H, Horrobin DF, Manku MS, Morse Fisher N. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan, 357
Kajimoto Y. *See* Nakai T
Kamoun A. *See* Chamba G
Kanagasabapathy AS. *See* Kuruvilla A
Karanth KS. *See* Kumar KB
Kassir S, Meltzer HL. Abnormal sensitivity of erythrocyte membrane Na/K ATPase of bipolar subjects to inhibition by calmodulin and calcium, 631
Kathol R. Environmental effects on creatinine, and on urinary-free cortisol, 1173-le
Kato N. *See* Iwanami A
Kay SR. *See* Iqbal N
Kaye WH. *See* Weltzin TE
Kean DM. *See* Blackwood DHR
Keegan DL. *See* Davis BA
Keith VA, Mansbach RS, Geyer MA. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle, 557
Kelly RH. *See* Chengappa KNR
Kemali D. *See* Monteleone P
Kempenaers C. *See* Mendlewicz J
Kennedy SH, Brown GM, McVey G, Garfinkel PE. Pineal and adrenal function before and after refeeding in anorexia nervosa, 216
Kern RS, Green MF, Satz P, Wirshing WC. Patterns of manual dominance in patients with neuroleptic-induced movement disorders, 483
Keshavan MS. *See* Chengappa KNR
Kessler C, Kling A. EEG power variation in schizophrenic subgroups: effects of emotionally salient stimuli, 335
Khot V. *See* Alexander RC
Kim SW, Dysken MW, Pandey GN, Davis JM. Platelet ^{3}H-imipramine binding sites in obsessive-compulsive disorder, 467
Kinney DK. *See* Woods BT
Kirch DG. *See* Alexander RC
Kirch DG. *See* Gold JM
Kirch DG. Where there's smoke . . . nicotine and ¡ sychiatric disorders, 107-ed
Kitamura N. *See* Nakai T
Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of *m*-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects, 973
Kling A. *See* Kessler C
Kornhuber A. *See* Schreiber H
Kornhuber HH. *See* Schreiber H
Koyama T. *See* Kusumi I
Kräuchi K, Haug H-J, Graw P. Alfred Hoche and the elimination of the unfit, 529-le
Kremen WS. *See* Lyons MJ
Kumar KB, Karanth KS. Enhanced retrieval of unpleasant memory in helpless rats, 493
Kupfer DJ, Ehlers CL, Frank E, Grochocinski VJ, McEachran AB. EEG sleep profiles and recurrent depression, 641
Kuruvilla A, Srikrishna G, Peedicayil J, Kuruvilla K, Kanagasabapathy AS. Serum prolactin levels in manic patients, 421

Kuruvilla K. *See* Kuruvilla A
Kusumi I, Koyama T, Yamashita I. Serotonin-stimulated CA^{2+} response is increased in the blood platelets of depressed patients, 310

Lader M. *See* Bruce M
Lagås PA, Ruokonen A. Late onset argininosuccinic aciduria in a paranoid retardate, 1229
Lake CR. Manic psychosis after coffee and phenylpropanolamine, 401
Laraia M. *See* Brady KT
Laraia MT. *See* Austin LS
Lauritzen L. *See* Mellerup ET
Lavie P. *See* Dagan Y
Lawlor BA. *See* Molchan SE
Lawlor BA. *See* Sunderland T
Lawlor BA, Sunderland T, Mellow AM, Molchan SE, Martinez R, Murphy DL. A pilot placebo-controlled study of chronic *m*-CPP administration in Alzheimer's disease, 140
Lee MA, Meltzer HY. Neuroendocrine responses to serotonergic agents in alcoholics, 1017
Legros J-J. *See* Wauthy J
Lejoyeux M, Mazière JC, Mora L, Auclair M, Mazière C. Sphingomyelinase fibroblast activity and psychoactive drugs, 841
Lemoine P. *See* Chamba G
Lerer B. *See* Silver H
Leventhal BL. *See* Perry BD
Levin B, Duchowny M. Childhood obsessive-compulsive disorder and cingulate epilepsy, 1049
Levinson DF. Skin conductance orienting response in unmedicated RDC schizophrenic, schizoaffective, depressed, and control subjects, 663
Levy R. *See* Beats B
Lim C. *See* DeVane CL
Linington BB. *See* Bracha HS
Lisjö P. *See* Westberg P
Litman R. *See* Hommer DW
Lohr J. *See* Caldwell CL
Lohr JB. *See* Bracha HS
Lowy MT. *See* Yehuda R
Lucey JV. *See* O'Flynn K
Luchins DJ. How about something practical?, 1179-ed
Lydiard RB. *See* Austin LS
Lydiard RB. *See* Brady KT
Lyons MJ, Merla ME, Young L, Kremen WS. Impaired neuropsychological functioning in symptomatic volunteers with schizotypy: preliminary findings, 424

MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study, 371
Machnee H. *See* O'Reilly R
Mackert A, Volz H-P, Stieglitz R-D, Müller-Oerlinghausen B. Phototherapy in nonseasonal depression, 257
Maes M, De Meester I, Vanhoof G, Scharpé S, Bosmans E, Vandervorst C, Verkerk R, Minner B, Suy E, Raus J. Decreased serum dipeptidyl peptidase IV activity in major depression, 577
Magliozzi JR. *See* Rapaport MH
Maj M. *See* Monteleone P
Mandeli J. *See* Schiavi RC
Manku MS. *See* Horrobin DF
Manku MS. *See* Kaiya H
Mann K. *See* Bartels M
Mansbach RS. *See* Keith VA
Mansour A. *See* Meador-Woodruff JH
Mårtensson B. *See* Bartfai A
Martin MJ. *See* Blackwood DHR
Martinez R. *See* Lawlor BA
Martinez R. *See* Molchan SE
Martinez RA. *See* Sunderland T
Martin-Loeches M, Garcia-Trapero J, Gil P, Rubia FJ. Topography of mobility and complexity parameters of the EEG in Alzheimer's disease, 1111
Mason GA. *See* Stern RA
Mason JW. *See* Yehuda R
Mastropaolo J. *See* Rosse RB
Mawhinney-Hee M. *See* Erwin RJ
Mazière C. *See* Lejoyeux M
Mazière JC. *See* Lejoyeux M
Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis, 475
McAllister C. *See* Rapaport MH
McCann UD, Penetar DM, Belenky G. Panic attacks in healthy volunteers treated with a catecholamine synthesis inhibitor, 413
McConaghy N. *See* Shelley AM
McConaha C. *See* Weltzin TE
McEachran AB. *See* Kupfer DJ
McEachron DL. *See* Stewart KT

McKee M. *See* Weltzin TE
McLeod DR. *See* Hoehn-Saric R
McManus DJ, Mousseau DD, Paetsch PR, Wishart TB, Greenshaw AJ. β-Adrenoreceptors and antidepressants: possible 2-phenylethylamine mediation of chronic phenelzine effects, 1122
McQueen JK. *See* Blackwood DHR
McVey G. *See* Kennedy SH
Meador-Woodruff JH, Mansour A. Expression of the dopamine D_2 receptor gene in brain*, 985
Mefford IN. *See* Gurguis GNM
Mellerup ET, Dam H, Lauritzen L, Plenge P. Platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with psychoactive drugs, 1056
Mellow AM. *See* Lawlor BA
Mellow AM. *See* Molchan SE
Meltzer HL. Is there a specific membrane defect in bipolar disorders?, 1071-ed
Meltzer HL. *See* Kassir S
Meltzer HL. *See* Placidi GF
Meltzer HY. *See* Bastani B
Meltzer HY. *See* Friedman L
Meltzer HY. *See* Lee MA
Mendlewicz J. *See* Staner L
Mendlewicz J, Kempenaers C, de Maertelaer V. Sleep EEG and amitryptiline treatment in depressed inpatients, 691
Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients, 109
Mercadante F. *See* Placidi GF
Merla ME. *See* Lyons MJ
Meyer VA. *See* Dahl RE
Michie PT. *See* Shelley AM
Minkoff JR. *See* Winograd CH
Minner B. *See* Maes M
Mita T. *See* Nakai T
Mizukawa R. ECT in long-term follow-up of BPD, 1172-le (response)
Mocaër E. *See* Chamba G
Modigh K. *See* Westberg P
Molchan SE. *See* Lawlor BA
Molchan SE. *See* Sunderland T
Molchan SE, Lawlor BA, Hill JL, Mellow AM, Davis CL, Martinez R, Sunderland T. The TRH stimulation test in Alzheimer's disease and major depression: relationship to clinical and CSF measures, 567
Monteleone P, Valente B, Maj M, Kemali D. Reduced lymphocyte response to PHA and OKT3 in drug-free and neuroleptic-treated chronic schizophrenics, 201
Mora L. *See* Lejoyeux M
Mormont C. *See* Wauthy J
Morse Fisher N. *See* Kaiya H
Moses JA Jr. *See* Faustman WO
Mouradian MM. *See* Heuser IJE
Mousseau DD. *See* McManus DJ
Muir WJ. *See* Blackwood DHR
Mukherjee S. *See* Reddy R
Müller N. *See* Botschev C
Müller-Oerlinghausen B. *See* Mackert A
Murphy CF. *See* Otto MW
Murphy DL. *See* Klein E
Murphy DL. *See* Lawlor BA
Murphy GM. *See* Csernansky JG
Murphy GM Jr, Ellis WG. The amygdala in Down's syndrome and familial Alzheimer's disease: four clinicopathological case reports, 92
Murphy JM. *See* Engleman EA
Murthy JN. *See* Reddy R

Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, Mita T, Tanaka C. Decreased histamine H_1 receptors in the frontal cortex of brains from patients with chronic schizophrenia, 349
Nakatani Y. *See* Iwanami A
Näsman B, Olsson T, Bäckström T, Eriksson S, Grankvist K, Viitanen M, Bucht G. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia, 684
Nelson DL. *See* Rapaport MH
Nelson HD. *See* Barkai AI
Nelson JC. *See* Mazure CM
Nemeroff C. *See* Roy-Byrne PP
Nemes Z, Rotrosen J, White T, Angrist B, Peselow E, Shoentag R, Brown KW. Serum iron and akathisia, 1064-le (response)
Nevels CT. *See* Stern RA
Newcomer JW. *See* Faustman WO
Nguyen NA. *See* Dahl RE
Nishino N. *See* Nakai T

O'Flynn K, O'Keane V, Lucey JV, Dinan TG. Effect of fluoxetine on noradrenergic mediated growth hormone release: a double blind, placebo-controlled study, 377
O'Keane V. *See* O'Flynn K
Olsson T. *See* Näsman B
O'Reilly R, Davis BA, Durden DA, Thorpe L, Machnee H, Boulton AA. Plasma phenyl-

ethylamine in schizophrenic patients, 145
Otto MW, Fava M, Rosenbaum JF, Murphy CF. Perceptual asymmetry, plasma cortisol, and response to treatment in depressed outpatients, 703

Paetsch PR. *See* McManus DJ
Pandey GN. *See* Kim SW
Pandey GN. *See* Sharma RP
Pangerl AM, Steudle A, Jaroni HW, Rüfer R, Gattaz WF. Increased platelet membrane lysophosphatidylcholine in schizophrenia, 837
Paterson IA. *See* Davis BA
Paul SM. *See* Rapaport MH
Peabody CA. *See* Winograd CH
Peedicayil J. *See* Kuruvilla A
Penetar DM. *See* McCann UD
Pepplinkhuizen L. *See* Fekkes D
Perel J. *See* Dahl RE
Perel J. *See* Weltzin TE
Perez-Stable EJ. *See* Callaway E
Perry BD, Cook EH Jr, Leventhal BL, Wainwright MS, Freedman DX. Platelet 5-HT_2 serotonin receptor binding sites in autistic children and their first-degree relatives, 121
Peselow E. *See* Nemes Z
Peskind ER. *See* Jensen CF
Pickar D. *See* Hommer DW
Pirke KM, Trimborn P, Platte P, Fichter M. Average total energy expenditure in anorexia nervosa, bulimia nervosa, and healthy young women, 711
Placidi GF, Mercadante F, Catalano D, Baschieri P, Dell'Osso L, Meltzer HL. Nuclear magnetic resonance spectrometry in mood disorder: a preliminary report, 210
Platte P. *See* Pirke KM
Plenge P. *See* Mellerup ET
Pollice C. *See* Weltzin TE
Posthumus Meyges FE. *see* van Gool WA
Prange AJ Jr. *See* Stern RA
Prohaska ML. *See* Stern RA
Prohovnik I. *See* Barkai AI
Puig-Antich J. *See* Dahl RE

Quincy C. *See* Chamba G
Quitkin FM. *See* Bruder GE

Rabin BS. *See* Chengappa KNR
Rapaport MH, Doran AR, Nelson DL, McAllister C, Magliozzi JR, Paul SM. Haloperidol and soluble interleukin-2 receptors, 1063-le
Raskind MA. *See* Jensen CF
Raus J. *See* Maes M
Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients, 409
Remillard AJ. *See* Davis BA
Renaud B. *See* Chamba G
Richmond JB, Eisenberg L. Putting the "public" back in mental health, the "mental" back in public health, 427-ed
Ringo DL. *See* Faustman WO
Risch SC. *See* Gillin JC
Ritchie J. *See* Roy-Byrne PP
Roehrs TA. *See* Rosenthal L
Rosen RC. Sleep and sexual function in the elderly male, 1-ed
Rosenbaum JF. *See* Otto MW
Rosenthal J. *See* Rosenthal L
Rosenthal L, Roehrs TA, Hayashi H, Zorick FJ, Wittig RM, Rosenthal J, Roth T. HLA DR2 in narcolepsy with sleep-onset REM periods but not cataplexy, 830
Rosenwasser AM. *See* Stewart KT
Rosse RB, Schwartz BL, Mastropaolo J, Goldberg RL, Deutsch SI. Subtype diagnosis in schizophrenia and its relation to neuropsychological and computerized tomography measures, 63
Roth T. *See* Rosenthal L
Rothmeier J. *See* Schreiber H
Rotrosen J. *See* Nemes Z
Roy-Byrne PP. *See* Cowley DS
Roy-Byrne PP. *See* Jensen CF
Roy-Byrne PP, Cowley DS, Hommer D, Ritchie J, Greenblatt D, Nemeroff C. Neuroendocrine effects of diazepam in panic and generalized anxiety disorders, 73
Roxborough HM. *See* Blackwood DHR
Rubia FJ. *See* Martin-Loeches M
Rüfer R. *See* Pangerl AM
Ruiz C. *See* Gillin JC
Ruokonen A. *See* Lagås PA
Ryan ND. *See* Dahl RE

Sahebarao MP. *See* Reddy R
Saleh S. *See* Davis BA
Sanberg PR. *See* Emerich DF
Sands J. *See* Harrow M
Sapolsky RM, Altmann J. Incidence of hypercortisolism and dexamethasone resistance increases with age among wild baboons, 1008

Sasaki K. *See* Fujisawa Y
Sassard J. *See* Chamba G
Satz P. *See* Kern RS
Scharpé S. *See* Maes M
Schiavi RC, Mandeli J, Schreiner-Engel P, Chambers A. Aging, sleep disorders, and male sexual function, 15
Schreiber H, Stolz-Born G, Rothmeier J, Kornhuber A, Kornhuber HH, Born J. Endogenous event-related brain potentials and psychometric performance in children at risk for schizophrenia, 177
Schreiner-Engel P. *See* Schiavi RC
Schuff N. *See* Bartels M
Schwartz BL. *See* Rosse RB
Schwartz JM. *See* Szuba MP
Seidenberg M. *See* Hermann BP
Sharma RP, Javaid JI, Pandey GN, Janicak PG, Davis JM. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients, 459
Shelhorse ME. *See* Stern RA
Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia, 1059
Sherman AD, Hegwood TS, Baruah S, Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics, 1191
Shimizu T. *See* Tachibana N
Shipley JE. *See* Taylor SF
Shiromani P. *See* Gillin JC
Shoentag R. *See* Nemes Z
Shook J. *See* Brady KT
Shrikhande S. *See* Davis BA
Silver H, Blacker M, Weller MPI, Lerer B. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study, 523
Southwick SM. *See* Yehuda R
Srikrishna G. *See* Kuruvilla A
Staner L, Bouillon E, Andrien M, Dupont E, Mendlewicz J. Lack of association between HLA-DR antigens and sleep-onset REM periods in major depression, 1199
St. Clair DM. *See* Blackwood DHR
Steber R. *See* Greil W
Stegeman GH. *See* Davis BA
Stern RA, Nevels CT, Shelhorse ME, Prohaska ML, Mason GA, Prange AJ Jr. Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: preliminary findings, 623
Steudle A. *See* Pangerl AM
Stewart JW. *See* Bruder GE
Stewart KT, McEachron DL, Rosenwasser AM, Adler NT. Lithium lengthens circadian period but fails to counteract behavioral helplessness in rats, 515
Stieglitz R-D. *See* Mackert A
Stolz-Born G. *See* Schreiber H
Streiner DL. *See* MacFarlane JG
Stuckstedte H. *See* Bartels M
Sugita Y. *See* Tachibana N
Sunderland T. *See* Lawlor BA
Sunderland T. *See* Molchan SE
Sunderland T, Berrettini WH, Molchan SE, Lawlor BA, Martinez RA, Vitiello B, Tariot PN, Cohen RM. Reduced cerebrospinal fluid dynorphin A_{1-8} in Alzheimer's disease, 81
Sutton L. *See* Gillin JC
Suy E. *See* Maes M
Szuba MP, Baxter LR Jr, Fairbanks LA, Guze BH, Schwartz JM. Effects of partial sleep deprivation on the diurnal variation of mood and motor activity in major depression, 817

Tachibana N, Sugita Y, Terashima K, Teshima Y, Shimizu T, Hishikawa Y. Polysomnographic characteristics of healthy elderly subjects with somnabulism-like behaviors, 4
Tanaka C. *See* Nakai T
Tandon R. *See* Taylor SF
Tandon R, Greden JF. Negative symptoms of schizophrenia: the need for conceptual clarity, 321-ed
Tariot PN. *See* Sunderland T
Taylor BS. *See* Winograd CH
Taylor SF, Tandon R, Shipley JE, Eiser AS. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia, 904
Taylor SF, Tandon R, Shipley JE, Eiser AS, Goodson J. Sleep onset REM periods in schizophrenic patients, 205
Tempesta E. *See* Ferro FM
Tenke C. *See* Bruder GE
Terao M. *See* Terao T
Terao T, Terao M, Yoshimura R, Abe K. Restless legs syndrome induced by lithium, 1167
Terao T, Yoshimura R, Abe K. Pericallosal arterial ectasia and manic-depressive illness, 526-le
Terashima K. *See* Tachibana N

Teshima Y. *See* Tachibana N
Thase ME. *See* Howland RH
Thompson S. *See* Alexander RC
Thorpe L. *See* O'Reilly R
Tingle D. *See* DeVane CL
Tollefson GD. Calcium channel blocker nimodipine for primary degenerative dementia, 1171-le (response)
Torrey EF. *See* Bracha HS
Towey JP. *See* Bruder GE
Trimborn P. *See* Pirke KM
Tuason VB. *See* Garvey M
Turner EH. *See* Hoffman WF

Uhde TW. *See* Gurguis GNM
Uhde TW. *See* Klein E

Valente B. *See* Monteleone P
van Calker D. *See* Greil W
Vandervorst C. *See* Maes M
van Gool WA, Waardenburg J, Posthumus Meyges FE, Weinstein HC, de Wilde A. The effect of tetrahydroaminoacridine (THA) on P300 in Alzheimer's disease, 953
Vanhoof G. *See* Maes M
Van Horn M. *See* Menza MA
van Praag HM. *See* Iqbal N
Veith RC. *See* Jensen CF
Verkerk R. *See* Maes M
Viitanen M. *See* Näsman B
Vitiello B. *See* Sunderland T
Volavka J. *See* Convit A
Volavka J. *See* Czobor P
Volz H-P. *See* Mackert A
von Frenckell R. *See* Wauthy J

Waardenburg J. *See* van Gool WA
Wainwright MS. *See* Perry BD
Ward PB. *See* Shelley AM
Ware MR. *See* DeVane CL
Warmann C. *See* Gillin JC
Wauthy J, Ansseau M, von Frenckell R, Mormont C, Legros J-J. Memory disturbances and dexamethasone suppression test in major depression, 736
Waziri R. *See* Sherman AD
Weinberger DR. *See* Daniel DG
Weinstein HC. *See* van Gool WA
Weller MPI. *See* Silver H
Weltzin TE, Hsu LKG, Pollice C, Kaye WH. Feeding patterns in bulimia nervosa, 1093
Weltzin TE, McConaha C, McKee M, Hsu LKG, Perel J, Kaye WH. Circadian patterns of cortisol, prolactin, and growth hormonal secretion during bingeing and vomiting in normal weight bulimic patients, 37
Westberg P, Modigh K, Lisjö P, Eriksson E. Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients, 247
Wetzler S. *See* Iqbal N
Wetzler S. *See* Kahn RS
White T. *See* Brown KW
White T. *See* Nemes Z
Widrow L. *See* Winograd CH
Winograd CH, Jacobson DH, Minkoff JR, Peabody CA, Taylor BS, Widrow L, Yesavage JA. Blood glucose and insulin response in patients with senile dementia of the Alzheimer's type, 507
Wirshing WC. *See* Kern RS
Wishart TB. *See* McManus DJ
Wisner KL. *See* Gracious B
Wittig RM. *See* Rosenthal L
Woods BT, Kinney DK, Yurgelun-Todd DA. Neurological "hard" signs and family history of psychosis in schizophrenia, 806
Wright BA, Jarrett DB. Lithium and calcium channel blockers: possible neurotoxicity, 635-le
Wyatt RJ. *See* Gold JM
Wyler AR. *See* Hermann BP

Yamashita I. *See* Kusumi I
Yang ZW. *See* Chengappa KNR
Yehuda R, Giller EL, Southwick SM, Lowy MT, Mason JW. Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder, 1031
Yesavage JA. *See* Winograd CH
Yonan CA. *See* Harrow M
Yoshimura R. *See* Terao T
Young AH. *See* Blackwood DHR
Young L. *See* Lyons MJ
Young WL. *See* Barkai AI
Yu PH. *See* Davis BA
Yurgelun-Todd DA. *See* Woods BT

Zealberg JJ. *See* Austin LS
Zhou FC. *See* Engleman EA
Zohar J. *See* Klein E
Zorick FJ. *See* Rosenthal L

Subject Index for Volume 30

Abnormal Involuntary Movement Scale
manual dominance patterns in patients with neuroleptic-induced movement disorders assessed via, 483
Acoustic startle
prepulse inhibition of, haloperidol failure to block effects of phencyclidine and dizocilpine on, 557
Acute Panic Inventory
panic and anxiety assessed via, 628
Adducin
in bipolar disorders, 1071-ed
Adenosinergic receptor systems
in neurobiology of panic disorder, 973
s-Adenosyl-1-methionine (SAMe)
against depression, 704
Adrenal glands
function of, in anorexia nervosa, 216
Adrenergic agonists
in panic attack induction, 413
Adrenocorticotropic hormone (ACTH)
in bulimia nervosa, 38
diazepam effect on levels of, 73
in Huntington's disease, 943
in major depressive disorder, 25
meta-chlorophenylpiperazine and, 1139
in panic disorder, 502
β-Adrenoreceptors
antidepressant effects on, 1122
Affective disorders
β-adrenergic function in, 739
fatty acid levels in, 357
monoamine hypothesis of, 421
among smokers, 107-ed
subsyndromal, 283
Afred Hoche
and elimination of the unfit, 529-le, 529-le (response)
Aggressive behavior
buspirone against, 88
EEG activity during, 363
serotonergic diet against, 88
Aging
dexamethasone resistance in, 1008
hypercortisolism in, 1008
melatonin production decrease in, 371
pineal function alterations in, 371
sleep disorders and male sexual function correlated with, 15
Agoraphobia
in panic disorder, 247
Akathisia
fluoxetine-induced, propranolol against, 531-le
serum iron levels in, 1064-le, 1064-le (response)
among smokers, 107-ed, 109
Alcoholism
depressed patients with, scopolamine injection and, 157
serotonergic function in, 1017
Alpha-1-acid glycoprotein
serum concentration, electroconvulsive therapy effect on, 116
Alpha-methyl-paratyrosine (AMPT)
in panic attack induction, 413
Alprazolam
against panic disorder, 49
Alzheimer's disease
adrenocortical axis in, 1008
amygdala in, 92
blood glucose and insulin response in, 507
cortisol in, 684
dehydroepiandrosterone sulfate in, 684
dynorphin A_{1-8} in, 81
EEG in, 1111
genetic linkage studies of, 213-ed
glycometabolism disturbance in, 1219
meta-chlorophenylpiperazine administration in, 140
nimodipine against, 1171-le, 1171-le (response)
tetrahydroaminoacridine effect on P300 in, 953
TRH stimulation test in, 567
Amenorrhea
in anorexia nervosa, 216
in bulimia nervosa, 37

Abbreviations:
ed: Editorial
le: Letter to the Editor

© 1991 Society of Biological Psychiatry

0006-3223/91/$03.50

2-Amino-3-hydroxy-5-methoxylisoxazole-4-propionic acid (AMPA)
in synaptosomal glutamate release, 1191
Amitriptyline
against depression, 600, 691
dopamine blocking activity of, 226
plasma phenylacetic acid levels and, 600
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
sphingomyelinase fibroblast activity and, 841
withdrawal from, 528-le
Amnestic disorder
dehydroepiandrosterone sulfate in, 684
Amphetamines
abuse of, as obsessive-compulsive disorder cause, 225
Amygdala
in Alzheimer's disease, 92
in Down's syndrome, 92
in schizophrenia, 383, 753
Anisocoria
manic depressive disorder accompanied by, 526-le
Ankyrins
in bipolar disorders, 1071-ed
Anorexia nervosa
average total energy expenditure in, 711
pineal and adrenal function before and after refeeding in, 216
Anthralinic acid
levels, in alcoholism, 1018
Anticardiolipin antibodies
immunoglobulin, in schizophrenia, 731
Anticholinergic agents
effect of on sleep and mood, 157
effect of on sphingomyelinase fibroblast activity, 841
Anticipatory saccades
maladaptive, in schizophrenia, 779
Antidepressants
β-adrenoreceptor function and, 1122
against chronic fatigue syndrome, 405
against panic disorder, 49, 248
suicidal preoccupation induced by, 190 (comment)
tricyclic. *See* Tricyclic antidepressants
Antidiuretic hormone (ADH)
demeclocycline in blockage of action of, 417
Antioxidant defense system
enzymes, in chronic schizophrenia, 409
Antipsychotic agents
withdrawal from, 528-le
Anxiety disorders
diazepam against, 73
DSM-III-R state anxiety symptoms in, 519
hypothalamic-pituitary-adrenal axis in, 502
lactate-induced, alprazolam vs. placebo treatment of, 49
Apomorphine
prepulse inhibition of startle blocked by, 557
Arecoline
REM sleep induced by, 151, 158
Arginosuccinic aciduria
late onset, in paranoid retardate, 1229
Attention deficits
in schizophrenia, 1059
Auditory evoked responses
midlatency, in schizophrenia, 430
Auditory oddball paradigm
in registrating late event-related potentials, 177
Autism
first-degree relatives in, 121
platelet 5-HT_2 serotonin receptor binding sites in, 121
Autoantibodies
against brain tissue, 201
Autoimmunity
in depression, 577
Awakening thresholds
from sleep stage 3-4, in war-related posttraumatic stress disorder, 618

Basal ganglia
neuroleptic-induced movement disorders and, 484
in schizophrenia, 383, 779
in tardive dyskinesia, 587
Beck Scale
mood state assessed via, 600, 1205
Benzodiazepines
against generalized anxiety disorder, 73
receptors for, in Huntington's disease, 944
Benztropine
effect of on polysomnographic measures in schizophrenia, 905
Bicuculline
in experimental induction of chorea, 944
Bingeing
effects of on hormonal circadian patterns, 37
Biperiden
effects of on REM sleep, 151, 158
Bipolar disorder
electroconvulsive therapy in, 1172-le, 1172-le (response)

erythrocyte membrane Na/K ATPase sensitivity in, 631
lethal catatonia similarity to, 197
psychosis with, 533-ed
specific defect in, 1071-ed
Birth complications
in etiology of schizophrenia, 326
Blood
peripheral, insulin levels in, in Alzheimer's disease, 1219
electroconvulsive therapy effect on regional flow of, 269
B lymphocytes
in schizophrenia, 201
Brain stem
activation of by electroconvulsive therapy, 269
Breathing
sleep-disordered, in male sexuality, 1, 15
Brief Psychiatric Rating Scale
schizophrenia assessed via, 431, 904, 927
Bromazepam
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Bulimia nervosa
average total energy expenditure in, 711
feeding patterns in, 1093
hormonal circadian patterns in, 37
Burns
alpha-1-acid glycoprotein levels and, 117
psychoactive drug binding amd, 117
Buspirone
against aggression, 88
neuroendocrine responses to in alcoholism, 1017

Ca^{2+}
serotonin-stimulated response of in blood platelets, in depression, 310
CaATPase
in bipolar disorders, 1072-ed
Caffeine
anxiogenic effects of in panic disorder, 973
plus propanolamine, manic psychosis after consumption of, 401
Calcium
erythrocyte membrane Na/K ATPase sensitivity to inhibition by, in bipolar disorder, 631
Calcium channel blockers
lithium combined with, neurotoxicity of, 635-le
against primary degenerative dementia, 1171-le, 1171-le (response)
Calmodulin
in bipolar disorders, 1071-ed
erythrocyte membrane Na/K ATPase sensitivity to inhibition by, in bipolar disorder, 631
Cancer
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117
Carbachol
REM sleep induced by, 151
Catalase
in schizophrenia, 409
Cataplexy
narcolepsy without, 830
Catatonia
lethal, 197
Catch-up saccades
in schizophrenia, 537
Catecholamines
in dysthymic disorder, 283
in panic disorder, 413, 502
Caudate
hyperdensity, in elderly depressives, 452
in schizophrenia, 753
CD^{+} cells
in depression, 577
Center for Epidemiological Studies-Depression Scale
mood state assessed via, 1205
Central dopaminergic tone
smoking effect on, 109
Cerebellar cortex
in schizophrenia, 795
Cerebellum
^{3}H-mepyramine binding in, 349
Cerebral arterial ectasia
in manic depressive disorder, 526-le
Cerebral blood flow
regional, electroconvulsive therapy effect on, 269
Cerebral injury
early, as cause of left-handedness, 326
Cerebral laterality
handedness in indexing of, 483
hormonal fluctuations in, 704
Cerebral ventricles
lack of bimodal distribution of size of, in schizophrenia, 887
Cerebrospinal fluid (CSF)
dynorphin A_{1-8} levels, in Alzheimer's disease, 81
5-hydroxyindoleacetic acid levels, in obsessive-compulsive disorder, 131, 467
insulin levels, in Alzheimer's disease, 1219
opioids, in panic disorder, 512

tryptophan levels, in alcoholism, 1018
CGI Scale
phototherapy against nonseasonal depression assessed via, 257
Childhood abuse
psychotic depression correlated with, 534-ed
Chlorimipramine
against obsessive-compulsive disorder, 131
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Chlorpromazine
neuroleptic dysphoria and, 844-le
polysomnographic measures in schizophrenia and, 905
sphingomyelinase fibroblast activity and, 841
Chlorprothixene
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Choleseatoma
of middle ear, manic depressive disorder accompanied by, 526-le
Cholesterol ester fatty acid levels
in plasma from schizophrenics, 357
Cholinergic overdrive
during withdrawal from antidepressants, 157
Chronic fatigue syndrome
integrative approach to understanding, 747-ed
nortriptyline against, 405
Cigarette smoking
psychiatric disorder frequency correlated with, 107-ed, 109
Cimetidine
^{3}H-mepyramine binding not inhibited by, 349
Cingulate cortex
in schizophrenia, 753
Circadian periodicity
hormonal, effects of binging and vomiting on, 37
lithium-induced lengthening of, 515
of sleep, melatonin influence on, 371
cis-dioxoline
REM sleep induced by, 151
Citalopram
neuroendocrine responses to in alcoholism, 1017
Clomipramine
memory affected by, 1075
against obsessive-compulsive disorder, 225, 467
against panic disorder, 247
Clonazepam
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Clonidine
growth hormone responses to, 73, 377
Clozapine
against schizophrenia, 771, 927
Cognitive deficits
in depression, 305
left-handedness and, 326
in major depression, 736
in tardive dyskinesia, 587
Columbia Unified Parkinson's Disease Rating Scale
manual dominance patterns in patients with neuroleptic-induced movement disorders assessed via, 483
Coma
water intoxication and, 417
Comment
Fluoxetine-induced suicidality, serotonin, and seasonality, 190
Limbic/mesolimbic connections and the pathogenesis of schizophrenia, 383
Complaint List
phototherapy against nonseasonal depression assessed via, 257
Computed tomography (CT)
in schizophrenia, 63, 887, 914
in tardive dyskinesia, 587
of ventricular enlargement in depression, 452
Conditioned emotional response
NMDA receptor blockade effects on acquisition of, 170
Confusion
water intoxication and, 417
Corpus callosum
in schizophrenia, 753
Correspondence
Alfred Hoche and the elimination of the unfit, 529, 529 (reponse)
Calcium channel blocker nimodipine for primary degenerative dementia, 1171, 1171 (response)
ECT in long-term follow-up of BPD, 1172, 1172 (response)
Environmental effects on creatinine, and on urinary-free cortisol, 1173
Haloperidol and soluble interleukin-2 receptors, 1063
Lithium and calcium channel blockers: possible neurotoxicity, 635
Lorazepam, amitriptyline, and sulpiride: withdrawal effects, 528
Neuroleptic depression in schizophrenia, 845, 847 (response)

Neuroleptic dysphoria in animals, 844
Opiate receptor antagonists for delusions of parasitosis, 530
Pericallosal arterial ectasia and manic-depressive illness, 526
Propranolol for fluoxetine-induced akathisia, 531
Serum iron and akathesia, 1064, 1064 (response)
Cortex
in pathogenesis of schizophrenia, 383
Corticotropin-releasing hormone (CRH)
in anorexia nervosa, 216
in bulimia nervosa, 38
in chronic fatigue syndrome, 750-ed
in Huntington's disease, 943
in hypothalamic pituitary function, 502
in panic disorder, 73
Cortisol
in alcoholism, 1017
in Alzheimer's disease, 684
in anorexia nervosa, 216
in bulimia nervosa, 37
in delusions of parasitosis, 530-le
in depression, 703
diazepam effect on levels of, 73
in Huntington's disease, 943
in lethal catatonia, 197
in major depression, 25
meta-chlorophenylpiperazine and, 1139
in multi-infarct dementia, 684
in obsessive-compulsive disorder, 131, 468
in panic disorder, 247, 502
in primate aging, 1008
in schizophrenia, 770
urinary-free, environmental effects on, 1173-le
Creatinine
environmental effects on, 1173-le
Crohn's disease
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117
"Cross-talk"
of second messenger-generating systems, 443
CT. *See* Computed tomography
Cyproheptadine
against chronic schizophrenia, 523
Cystathionine-β-synthase
specific activity of in fibroblasts, 966

d2 attention test
children at risk for schizophrenia assessed via, 177
Daytime alertness
in chronic insomnia, melatonin effects on, 371
Dehydroepiandrosterone sulfate
in Alzheimer's disease, 684
in amnestic disorder, 684
in multi-infarct dementia, 684
Delusions
depression with, 533-ed
of parasitosis, opiate receptor antagonists against, 530-le
Demeclocycline
against polydipsia-hyponatremia in chronic psychosis, 417
Dementia
buspirone against aggressive behavior in persons with, 88
Depression
adrenocortical axis in, 1008
alcoholism with, scopolamine treatment of, 157
amitriptyline against, 691
in anorexia nervosa, 216
caudate hyperdensity in, 452
combined thyroid hormone treatment and electroconvulsive therapy against, 623
cortisol levels in, 25, 703
dysthymic disorder associated with, 283
in elderly, 452
event-related potentials in, 233
frontal lobes in, 1205
5-hydroxytryptophan response suppression and, 317
hypersensitive postsynaptic serotonin receptor theory of, 317
imipramine plus desipramine against, 57
immune response in, 577
learned helplessness in, 515
natural killer cell activity in, 1131
neurocognition in, 305
neuroendocrine abnormalities in, 73
neuroleptic, in schizophrenia, 845-le, 847-le (response)
nonseasonal, phototherapy against, 257
nuclear magnetic resonance spectrometry in, 210
in panic disorder, 247
perceptual assymetry in, 703
phenylacetic acid concentrations in, 600
prolactin response to metoclopramide in, 313
psychotic, 533-ed
recurrent, EEG sleep profiles in, 641
serotonin-stimulated Ca^{2+} response of blood platelets in, 310
skin conductance orienting response in, 663

among smokers, 107-ed
tianeptine effect on serotonin platelet uptake in, 609
unpleasant memory retrieval in, 493
ventricular enlargement in, 452
Depression Scale
photootherapy against nonseasonal depression assessed via, 257
Desipramine
β-adrenoreceptors and, 1122
growth hormone release mediated by, 377
ineffectiveness of against obsessive-compulsive disorder, 225
plus imipramine, against depression, 57
sphingomyelinase fibroblast activity and, 841
Development
pineal function alterations in course of, 371
in schizophrenia, 326
Developmental disabilities
buspirone against aggressive behavior in persons with, 88
Developmental neurobiology
and clinical course, 963-ed
Dexamethasone suppression test (DST)
in bulimia nervosa, 37
in depression, 703
in dysthymic disorder, 283
in Huntington's disease, 943
in lethal catatonia, 197
in major depression, 736
in panic disorder, 247
in primate aging, 1008
Diazepam
against generalized anxiety disorder, 73
against panic disorder, 73
Dichotic listening tasks
perceptual assymetries indicated by, 703
Dihomogammalinoleic acid (DGLA)
in schizophrenia, 795
5,7-Dihydroxytryptamine
raphe lesions, potentiated 5-hydroxytryptophan response suppression following, 317
Dipeptidyl peptidase IV
activity, in major depression, 577
Diphenylhydantoin
against panic disorder, 628
Diphenylhydramine
^{3}H-mepyramine binding inhibited by, 349
Diphenylpyraline
^{3}H-mepyramine binding inhibited by, 349
Disulfiram
against panic disorder, 628
Dizocilpine
effects of on prepulse inhibition of startle, failure of haloperidol to block, 557
Dopamine
agonists, prepulse inhibition of startle blocked by, 557
antagonists, prolactin response to in depression, 313
blocking activity, of clomipramine in obsessive-compulsive disorder, 225
D_2 receptor gene, expression of in brain, 985
hypothesis, of schizophrenia, 383
in mania, 421
neurotransmission, methylphenidate effects on, 459
nicotine-stimulated release of from nigrostriatal neurons, 109
in panic disorder, 502
phenylethylamine synergy with in schizophrenia, 145
systems, adaptive capacity of, 383
Dorsal raphe
activation of by electroconvulsive therapy, 269
Double-labeled water method
for measurement of average daily total energy expenditure, 711
Down's syndrome
amygdala in, 92
Doxepin
against panic disorder, 628
Dynorphin A_{1-8}
in Alzheimer's disease, 81
in panic disorder, 512
Dysphoria
neuroleptic, 844-le, 845-le, 847-le (response)
Dysthymic disorder
biological studies of, 283

Ear assymetries
in depression, 703
ECT. *See* Electroconvulsive therapy
Editorial
Annual meeting theme for 1992: developmental neurobiology and clinical course, 963
Biological research in geriatric psychiatry, 855
Chronic fatigue syndrome: the need for an integrative approach, 747
How about something practical?, 1179
Is investment in molecular genetics worthwhile?, 213
Is there a specific defect in bipolar disorders?, 1071

Negative symptoms of schizophrenia: the need for conceptual clarity, 321
Putting the "public" back in mental health, the "mental" back in public health, 427
Sleep and sexual function in the elderly male, 1
What we don't know about psychotic depression, 533
EEG. *See* Electroencephalogram
Eicosanoids
in schizophrenia, 357, 795
Eicosapentaenoic acid
in schizophrenia, 357
Elderly
biological research in geriatric psychiatry and, 855-ed
caudate hyperdensity in, 452
depression in, 452
men, sleep and sexual function in, 1-ed
nocturnal somnabulism-like behaviors in, 4
psychosis in, 855-ed
ventricular enlargement in, 452
Electroconvulsive therapy (ECT)
alpha-1-acid glycoprotein concentration and, 116
in bipolar disorder follow-up, 1172-le, 1172-le (response)
local cerebral blood flow and glucose uptake altered by, 269
thyroid hormone treatment combined with, against depression, 623
Electrodermal activity
in dysthymic disorder, 283
Electroencephalogram (EEG)
in Alzheimer's disease, 1111
in depression, 641, 691
in dysthymic disorder, 283
lateralized abnormality of in persistently violent psychiatric patients, 363
male sexual function and, 15
in obsessive-compulsive disorder with cingulate epilepsy, 1049
in schizophrenia, 335, 430, 904, 927
Electromyelographic (EMG) activity
tonic, with stage-1 REM sleep in somnabulism-like behaviors, 4
Emotionally salient stimuli
effect of on EEG power variation in schizophrenic subgroups, 335
β-Endorphins
in panic disorder, 512
Energy expenditure
average total daily, in eating disorders, 711
Epilepsy
alpha-1-acid glycoprotein concentrations in, 116
cingulate, obsessive-compulsive disorder association with, 1049
psychoactive drug binding in, 117
unilateral temporal lobe, mood state in, 1205
Epstein-Barr virus (EBV)
in chronic fatigue syndrome, 749-ed
Erectile dysfunction
during sleep, in elderly men, 1-ed, 15
Erythrocytes
in bipolar disorders, 631, 1071-ed
in schizophrenia, 837, 841
Essential fatty acids
in schizophrenia, 357, 795
Event-related potentials
in children at risk for schizophrenia, 177
in depression, 233
in schizophrenia, 430
Excitatory amino acid blockade
effect of on development of learned emotional response, 170
Extrapyramidal symptoms
manual dominance patterns and, 483
in schizophrenia, 913
Extrapyramidal syndromes
psychopathology of, smoking correlated with, 109
Eye tracking dysfunction
in schizophrenia, 753, 779
^{19}F nuclear magnetic resonance (^{19}F-NMR) spectroscopy
of trifluoperazine and fluphenazine, 656
Family history
of psychosis in schizophrenia, 806
Fatty acids
in schizophrenia, 357, 795
Fentanyl
against delusions of parasitosis, 530-le
Finger pulse volume
transient reductions in, 664
First-degree relatives
of autistic children, 121
Flunitrazepam
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Fluoxetine
akathisia induced by, propranolol against, 531-le
dopamine blocking properties of, 225
neuroendocrine responses to in alcoholism, 1017
noradrenergic mediated growth hormone release and, 377

against obsessive-compulsive disorder, 467
plasma phenylacetic acid concentrations in depression and, 600
suicidal preoccupation induced by, 190 (comment)
Fluphenazine
^{19}F nuclear magnetic resonance spectroscopy of, in human brain, 656
against schizophrenia, 905, 927
Fluspirilene
against delusions of parasitosis, 530-le
Fluvoxamine
against obsessive-compulsive disorder, 467
^{19}F-NMR. *See* ^{19}F nuclear magnetic resonance spectroscopy
Food consumption
hormonal release influenced by, 37
Formylmethionylleucylphenylalanine (*f* MLP)
in inositol phosphate accumulation in neutrophils, 443
Frontal cortex
in schizophrenia, 349, 753, 795
Frontal lobes
in bipolar depression, 210
in depression, 1205
perseverative errors associated with dysfunction of, 63
in persistently violent psychiatric inpatients, 363
in schizophrenia, 1182

Gain smooth pursuit tracking
in schizophrenia, 537
Galanin
CSF measures of, in Alzheimer's disease, 81
Gamma-aminobutyric acid (GABA)
in anxiety, 73
in Huntington's disease, 943
in schizophrenia, 780, 1191
Gas chromatography-mass spectrometry negative chemical ionization method
for quantification of plasma phenylethylamine in schizophrenics, 145
Gaussian mixture analysis
of lack of bimodal distribution of ventricular size in schizophrenia, 887
Generalized anxiety disorder
DSM-III-R state anxiety symptoms in, 519
Genes
dopamine D_2 receptor, expression of in brain, 985
predisposing to psychosis, 719
in schizophrenia, 754
Geriatric psychiatry
biological research in, 855-ed
Glucocorticoids
deficiency of, overlap of with chronic fatigue syndrome, 750-ed
feedback resistance of, in primate aging, 1008
Glucose
in Alzheimer's disease, 507, 1219
blood to brain flow of, electroconvulsive therapy effect on, 269
Glutamate
NMDA-mediated release of, in synaptosomes of schizophrenics, 1191
postsynaptic receptor activated by, 170
in schizophrenia, 383
Glutathione peroxidase (GSHPx)
in schizophrenia, 409
Gonadotropin-releasing hormone (GRH)
in anorexia nervosa, 216
Growth hormone (GH)
in bulimia nervosa, 37
diazepam effect on levels of, 73
in major depression, 25
methylphenidate effect on levels of, 459
noradrenergic mediated release of, fluoxetine effect on, 377

Hallucinations
depression with, 533-ed
in narcolepsy, 830
Haloperidol
failure of to block effects of phencyclidine and dizocilpine on prepulse inhibition of startle, 557
neuroleptic dysphoria and, 844-le
against schizophrenia, 905, 927, 1063-le
Hamilton Anxiety Scale
panic disorder assessed via, 247
Hamilton Depression Scale
major depression assessed via, 57, 257, 600, 691, 817
Hand ectoderm
prenatal maldevelopment of, in schizophrenia, 719
Handedness
in male schizophrenics, 326
in patients with neuroleptic-induced movement disorders, 483
in persistent violent behavior, 363
Head injury
buspirone against aggressive behavior in persons with, 88

Hillside Akathisia Scale
parameters of, 532-le
Hippocampus
^{3}H-mepyramine binding in, 349
in schizophrenia, 383, 753
tianeptine enhancement of extracellular 5-hydroxyindoleacetic acid in, 610
Histamine H_1 receptors
decreased, in frontal cortex of schizophrenics, 349
HLA DR antigens
in major depression, 1199
in narcolepsy without cataplexy, 830
Homovanillic acid (HVA)
in acute psychosis, 475
in Alzheimer's disease, 81
methylphenidate effect on levels of, 459
in panic disorder, 502
Huntington's disease
limbic-hypothalamic-pituitary-adrenal axis in, 943
8-Hydroxy-2(di-*n*-propylamino) tetraline (8-OH-DPAT)
neuroendocrine responses to, in alcoholism, 1017
6-Hydroxydopamine
in studies of autoreceptor role of midbrain D_2 receptors, 985
5-Hydroxyindoleacetic acid (5-HIAA)
in alcoholism, 1018
in Alzheimer's disease, 81
memory and, 1075
in obsessive-compulsive disorder, 131, 467
tianeptine effect on, 610
Hydroxyl radicals
in schizophrenia, 409
5-Hydroxytryptamine. *See* Serotonin
5-Hydroxytryptophan
neuroendocrine responses to in alcoholism, 1017
response, following 5,7-dihydroxytryptamine raphe lesions in animal model of depression, 317
Hyperpyrexia
in lethal catatonia, 197
Hypersensitive postsynaptic serotonin receptor theory
of depression, 317
Hypertension
propranolol against, 739
Hypnagogic hallucinations
in narcolepsy, 830
Hyponatremia
in chronic psychosis, demeclocycline against, 417
Hypothalamic-pituitary-adrenal (HPA) axis
in anxiety disorders, 73
in bulimia nervosa, 37
in chronic fatigue syndrome, 750-ed
in depression, 703
in major depressive disorder, 25, 736
in panic disorder, 502
in posttraumatic stress disorder, 1031
Hypothalamic-pituitary-thyroid (HPT) axis
electroconvulsive therapy effect on, 623
Hypothalamus
^{3}H-mepyramine binding in, 349

Imipramine
β-adrenoreceptors and, 1122
dopamine blocking activity of, 226
against obsessive-compulsive disorder, 131, 467
against panic disorder, 247
plus desipramine, against depression, 57
sphingomyelinase fibroblast activity and, 841
tritiated probe binding to, 1056
Immune system
anticardiolipin antibodies and, 731
in chronic fatigue syndrome, 749-ed
in depression, 577
neuroleptic effects on, 201
in schizophrenia, 201, 731
Indoleacetic acid
levels, in alcoholism, 1018
Inferior colliculi
activation of by electroconvulsive therapy, 269
Inflammatory disease states
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117
Inositol phosphates
agonist-stimulated accumulation of, attenuation of in neutrophils from male patients under lithium therapy, 443
in alcoholism, 1018
Insomnia
chronic, melatonin effects on total sleep time and daytime alertness in, 371
Insulin
response, in Alzheimer's disease, 507, 1219
Interleukin-2 (IL-2)
activity, in depression, 577
receptors, in schizophrenia, 1063-ed
Iron
serum, in akathisia, 1064-le, 1064-le (response)
Isocarboxazid

against depression, 601

Japan
fatty acids in plasma of schizophrenics from, 357

Kappa binding
increased, of Alzheimer brains at autopsy, 81

Lactate
vulnerability, after alprazolam vs. placebo treatment of panic disorder, 49
Lateralized abnormality
in EEG of persistently violent psychiatric inpatients, 363
Lateral ventricles
in schizophrenia, 753
Learned helplessness
lithium ineffectiveness in counteracting, 515
unpleasant memory retrieval and, 493
Lentiforme complex
in Huntington's disease, 944
Lethargy
water intoxication and, 417
Leukocytes
in depression, 577
Limbic-hypothalamic-pituitary-adrenal (LHPA) axis
in Huntington's disease, 943
Limbic structures
in pathogenesis of schizophrenia, 383
Linoleic acid
in schizophrenia, 357
Lithium
agonist-stimulated accumulation of inositol phosphates attenuated in neutrophils by, 443
against bipolar disorder, 631, 1071-ed
calcium channel blockers combined with, neurotoxicity of, 635-le
learned helplessness behavior not counteracted by, 515
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
restless legs syndrome induced by, 1167
Local circuit neurons hypo(dys)function hypothesis
of schizophrenia, 857
Long-term potentiation
induction of, 170
Lorazepam
withdrawal from, 528-le
Luria-Nebraska Neuropsychological Battery
handedness in schizophrenia associated with increased impairment on, 326
Lymphocytes
in depression, 577
Lysergic acid diethylamide (LSD)
binding of to postsynaptic 5-HT$_2$ receptors, 771
Lysophosphatidylcholine
in schizophrenia, 837

M_1 receptors
in REM sleep regulation, 151
Magnetic resonance imaging (MRI)
in schizophrenia, 753, 857, 887
Major depressive disorder
amitriptyline against, 691
dexamethasone suppression test in, 736
dipeptidyl peptidase IV activity in, 577
dysthymic disorder associated with, 283
growth hormone response to desipramine in, 377
HLA-DR antigens and sleep onset REM periods in, 1199
lethal catatonia similarity to, 197
memory disturbances in, 736
natural killer cell activity in, 1131
neurocognition in, 305
nonseasonal, phototherapy against, 257
P3 latency in, 233
partial sleep deprivation in, 817
posttraumatic stress disorder similarity to, 1031
among smokers, 107-ed
TRH stimulation test in, 567
24-hour cortisol measures in adolescents with, 25
Mania
serum prolactin levels in, 421
Manic depressive disorder
genetic linkage studies of, 213-ed
lithium against, 443
pericallosal arterial ectasia in, 526-le
Manic psychosis
after coffee and propanolamine, 401
Maprotiline
against depression, 601
dopamine blocking activity of, 226
Maudsley Obsessional-Compulsive Inventory
parameters of, 131
McN-A-343 M_1 agonist
lack of effect of on REM sleep, 151
Melancholia
perceptual assymetries in, 704
Melatonin
in anorexia nervosa, 216

effects of on total sleep time and daytime alertness in chronic insomnia, 371
Memory
clomipramine effects on, 1075
effects of combined thyroid hormone treatment and electroconvulsive therapy on, 623
in major depression, 736
in schizophrenia, 781
unpleasant, enhanced retrieval of in helpless rats, 493
Menstrual cycle
cognitive function changes across, 704
serotonin levels and, 88
Mental retardation
arginosuccinic aciduria in, 1229
buspirone against aggressive behavior in persons with, 88
neurocognition in, 305
Mepyramine
^{3}H-mepyramine binding inhibited by, 349
Mesolimbic structures
in pathogenesis of schizophrenia, 383
Meta-chlorophenylpiperazine (*m*-CPP)
in Alzheimer's disease, 140
anxiogenic effects of in panic disorder, 973
in obsessive-compulsive disorder, 131, 468
in schizophrenia, 770
as serotonin function probe, 1139
Methamphetamine
psychosis due to, P300 component in, 726
3-Methoxy-4-hydroxyphenylglycol (MHPG)
in acute psychosis, 475
in Alzheimer's disease, 81
in panic disorder, 502
Methylphenidate
effects of in schizophrenic and nonschizophrenic patients, 459
Metoclopramide
prolactin response to, in depression, 313
Mianserin
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Midlatency auditory evoked responses
in schizophrenia, 430
Mismatch negativity
in schizophrenia, 1059
Mitogen-induced blast transformation
blunted, in depression, 577
Mitogens
lymphocyte response to, in schizophrenia, 201
MK-212
in alcoholism, 1017
in obsessive-compulsive disorder, 131
MK-801 NMDA receptor antagonist
effect of on conditioned emotional response, 170
Molecular genetics
investment in, 213-ed
Monoamine hypothesis
of affective disorders, 421
Monoamine metabolites
in Alzheimer's disease, 81
Monoamine oxidase (MAO) inhibitors
β-adrenoreceptors and, 1122
against depression, 601
against panic disorder, 49
Montgomery-Åsberg Depression Scale
panic disorder assessed via, 247
Mood
disorders, nuclear magnetic resonance spectrometry in, 210
partial sleep deprivation effect on, in major depression, 817
scopolamine effect on, 157
in unilateral temporal lobe epilepsy, 1205
Motor activity
partial sleep deprivation effect on, in major depression, 817
Movement disorders
manual dominance in, 483
in schizophrenia, 1182
among smokers, 107-ed, 109
Multi-infarct dementia
cortisol in, 684
serum dehydroepiandrosterone sulfate in, 684
Multiple sleep latency test
narcolepsy assessed via, 830
Muscarinic antagonists
dose dependent inhibition of REM sleep by, 151
Muscle atonia
in induction of somnabulism-like behaviors, 4
male sexual function and, 15
Myocardial infarction
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117

N1 event-related potential component
in depression, 234
in schizophrenia, 1059
N2 event-related potential component
in children at risk for schizophrenia, 177
Na/K ATPase
in bipolar disorder, 631, 1071-ed
Naloxone
against delusions of parasitosis, 530-le

neuroleptic dysphoria and, 844-le
Naltrexone
against delusions of parasitosis, 530-le
Narcolepsy
without cataplexy, HLA DR2 in, 830
National program
comprehensive, for mental health, 427-ed
Natural killer cells
cytotoxicity of, in depression, 1131
Neurocognition
in depression, 305
Neurofibrillary tangles
in Alzheimer's disease, 92
in Down's syndrome, 92
Neuroleptic radioreceptor assay
of plasma samples from obsessive-compulsive disorder patients, 225
Neuroleptics
antihistaminic H_1 properties of, 350
^{19}F nuclear magnetic resonance spectroscopy of, 656
immune system effects of, 201
manual dominance in movement disorders induced by, 483
polysomnographic measures in schizophrenia and, 904
smoking effect on blood levels of, 109
Neuropeptide Y (NPY)
in Alzheimer's disease, 81
Neutrophils
agonist-stimulated accumulation of inositol phosphates in, 443
Nicotine
use, psychiatric disorder frequency correlated with, 107-ed, 109
Niemann-Pick's disease
lysosomal sphingomyelinase deficiency in, 841
Nifedipine
lithium combined with, safety of, 635-le
Nigrostriatal neurons
nicotine-stimulated dopamine release from, 109
Nimodipine
against primary degenerative dementia, 1171-le, 1171-le (response)
Nitrazepam
platelet ^3H-imipramine and ^3H-paroxetine binding during treatment with, 1056
N-methyl-*d*-aspartate (NMDA)
dizocilpine as noncompetitive antagonist of, 557
glutamate release mediated by, in synaptosomes of schizophrenics, 1191
receptor blockade, effects of on acquisition of conditioned emotional response, 170
NMR. *See* Nuclear magnetic resonance
Nonvisually guided saccade-adaptive anticipatory saccade task
schizophrenia assessed via, 781
β-Noradrenergic blockade
response bias and, 739
Noradrenergic function
memory and, 1075
in panic disorder, 413, 502
in posttraumatic stress disorder, 618
Norepinephrine
in autism, 121
in mania, 421
Nortriptyline
against chronic fatigue syndrome, 405
dopamine blocking activity of, 226
against panic disorder, 628
platelet ^3H-imipramine and ^3H-paroxetine binding during treatment with, 1056
Nuclear magnetic resonance (NMR)
in mood disorders, 210
of trifluoperazine and fluphenazine, 656
Nucleus accumbens
in pathogenesis of schizophrenia, 383

Obsessive-compulsive disorder
cingulate epilepsy association with, 1049
clomipramine against, 225, 467
fluoxetine against, 467
fluvoxamine against, 467
imipramine against, 131, 467
serotonin uptake in, 131
OKT3 monoclonal antibody
lymphocyte response to, in schizophrenia, 201
Oleic acid
in schizophrenia, 357
Oligomenorrhea
in bulimia nervosa, 37
Opiate receptors
Opiates
in Alzheimer's disease, 81
prolactin response to, in depression, 313
Opioids
in panic disorder, 512
Orofacial ultrasonography
of tardive dyskinesia, 483
Osteoarthritis
genetic linkage studies of, 213-ed
Oxazepam
platelet ^3H-imipramine and ^3H-paroxetine binding during treatment with, 1056

Oxotremorine-M
REM sleep induced by, 151
Oxyradicals
in schizophrenia, 409

P1 event-related potential component
in schizophrenia, 430
P2 event-related potential component
in depression, 234
in schizophrenia, 1059
P3 event-related potential component
in children at risk for schizophrenia, 177
in depression, 233
P50 event-related potential component
in schizophrenia, 430
P300 event-related potential component
in Alzheimer's disease, 953
in methamphetamine psychosis, 726
in schizophrenia, 753
P350 event-related potential component
in children of schizophrenics, 178
P400 event-related potential component
in children of schizophrenics, 178
Pallidum
^{3}H-mepyramine binding in, 349
Panic disorder
agoraphobia with, 247
alprazolam against, 49
AMPT in, 413
caffeine in, 973
CSF opioids in, 512
diazepam against, 73
DSM-III-R state anxiety symptoms in, 519
dynorphin A $_{1-8}$ in, 512
β-endorphins in, 512
hypertonic saline infusion-induced panic in, 628
hypothalamic-pituitary-adrenal axis in, 502
meta-chlorophenylpiperazine in, 973
placebo treatment of, 49
postdexamethasone serum cortisol levels in, 247
Papio cynocephalus
hypercortisolism and dexamethasone resistance in, 1008
Para-chlorophenylalanine (PCPA)
neuroendocrine responses to, in alcoholism, 1017
Parahippocampal gyrus
in schizophrenia, 753
Paralysis
sleep, in narcolepsy, 830
Paranoia
arginosuccinic aciduria with, 1229
fatty acid levels in, 357
schizophrenia associated with, 63, 145
Parasitosis
delusions of, opiate receptor antagonists against, 530-le
Parkinsonism
manual dominance patterns in, 483
in schizophrenia, 913, 1182
among smokers, 107-ed, 109
Paroxetine
tritiated, binding of during treatment with psychoactive drugs, 1056
Partial sleep deprivation
against major depression, 817
Penfluridol
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Penile tumescence
nocturnal, aging and sleep disorders correlated with, 1-ed, 15
Perceptual assymetry
in depressed outpatients, 703
Pericallosal arterial ectasia
in manic depressive disorder, 526-le
Periodic leg movements
during sleep, male sexual function and, 1-ed, 15
Perphenazine
elixir, against acute psychosis, 475
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Perseverative errors
in schizophrenia, 63
Personality disorders
neurocognition in, 305
PET. *See* Positron emission tomography
Phasic phenomena
increased, in induction of somnabulism-like behaviors, 4
Phencyclidine
effects of on prepulse inhibition of startle, failure of haloperidol to block, 557
Phenelzine
β-adrenoreceptors and, 1122
against depression, 601
Phenothiazines
effect of on sphingomyelinase fibroblast activity, 841
Phenylacetic acid
in depression, 600
Phenylethylamine
mediation, of chronic phenelzine effects on β-adrenoreceptors, 1122

in schizophrenia, 145
Phenylpropanolamine
plus caffeine, manic psychosis after consumption of, 401
Phosphatidylethanolamine
fatty acid composition of, in schizophrenia, 795
Phospholipids
in schizophrenia, 357, 837
Phototherapy
against nonseasonal depression, 257
against seasonal affective disorder, 257
Physostigmine
P300 latency and, 953
REM sleep induced by, 151
Phytohemagglutinin (PHA)
lymphocyte response to, in schizophrenia, 201
Pilocarpine
REM sleep induced by, 151
Pimozide
against delusions of parasitosis, 530-le
polysomnographic measures in schizophrenia and, 905
Pineal gland
in anorexia nervosa, 216
in melatonin production, 371
Platelets
^{3}H-imipramine binding sites in, 467, 1056
lysophosphatidylcholine in, in schizophrenia, 837
in obsessive-compulsive disorder, 131
^{3}H-paroxetine binding sites in, 1056
serotonin-stimulated Ca^{2+} response in, in depression, 310
Pneumoencephalography
in schizophrenia, 887
Pneumonia
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117
Polydypsia-hyponatremia
in chronic psychosis, demeclocycline against, 417
Polysomnographic studies
in schizophrenia, effect of neuroleptic treatment on, 904
of somnabulism-like behaviors in elderly subjects, 4
Positive and Negative Syndrome Scale
schizophrenia assessed via, 770
Positron emission tomography (PET)
neuroleptics in brain and, 656
in schizophrenia, 857
Posttraumatic stress disorder (PTSD)
hypothalamic-pituitary-adrenal axis in, 1031
war-related, awakening thresholds from sleep stage 3-4 in, 618
Preattentive processing deficit
in schizophrenia, 1059
Prefrontal cortex
in schizophrenia, 779
Prenatal development
in etiology of schizophrenia, 326, 719
Profile of Mood States
major depression assessed via, 817
Prolactin
in alcoholism, 1017
in bulimia nervosa, 37
in depression, 313
in mania, 421
meta-chlorophenylpiperazine and, 1139
in obsessive-compulsive disorder, 131, 468
in schizophrenia, 770
Promethazine
^{3}H-mepyramine binding inhibited by, 349
Propranolol
against fluoxetine-induced akathisia, 531-le
against hypertension, 739
response bias on memory scanning task and, 739
Prostaglandin E_1 (PGE_1)
in schizophrenia, 357, 795
Psychometric performance
in children at risk for schizophrenia, 177
Psychomotor retardation
in major depression, 233
Psychosis
arginosuccinic aciduria in, 1229
after coffee and propanolamine, 401
depression with, 533-ed
in elderly, 855-ed
family history of, 806
genes predisposing to, 719
handedness in predisposition to, 327
methamphetamine-induced, 726
methylphenidate effect on, 459
P300 component in, 726
plasma free homovanillic acid as predictor of clinical response in, 475
polydypsia-hyponatremia in, 417
in schizophrenia, 383, 806
serum factor-induced changes in serine metabolism in, 966
Public health
comprehensive national program for, 427-ed
Putamen
^{3}H-mepyramine binding in, 349

Quinpirole
prepulse inhibition of startle blocked by, 557

Raphe
lesions, 5,7-dihydroxytryptamine, in animal model of depression, 317
Rapid eye movement (REM) sleep
biperiden-induced inhibition of, 151
in depression, 691
in dysthymic disorder, 283
in major depression, 25, 1199
in narcolepsy without cataplexy, 830
in recurrent depression, 641
in schizophrenia, 205, 904
scopolamine effect on, 157
stage 1, with tonic EMG activity, 4
Research Diagnostic Criteria
for depression, 691
for mental illness, 663
Respiratory disturbances
sleep-related, male sexual function and, 1-ed, 15
Response bias
on memory scanning task, in depression treated with β-noradrenergic blockade, 739
Restless legs syndrome
lithium-induced, 1167
Rey Memory Profile
major depression assessed via, 736
Rheumatoid arthritis
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117
Risperidone
against schizophrenia, 771
Ritanserin
against schizophrenia, 771
RS 86
REM sleep induced by, 151, 158

Saccadic eye movements
in schizophrenia, 779
Salbutamol
motor suppressant action of, as measure of β-adrenergic receptor sensitivity, 1122
Saline infusion
hypertonic, panic induced by in panic disorder, 628
Scale for the Assessment of Negative Symptoms
schizophrenia assessed via, 904
Schizoaffective disorders
skin conductance orienting response in, 663
Schizophrenia
anticardiolipin antibodies in, 731
antioxidant defense system enzymes in, 409
cyproheptadine against, 523
dopaminergic dysfunction in, 985
EEG power variation in, 335
psychometric performance in children at risk for, 177
extrapyramidal symptoms in, 913
fatty acid levels in, 357, 795
frontal lobes in, 1182
genetic linkage studies of, 213-ed
haloperidol against, 927, 1063-le
histamine H_1 receptors in, 349
immune mechanisms in, 201
interleukin-2 receptors in, 1063-le
left-handedness in, 326
limbic/mesolimbic connections in pathogenesis of, 383
local circuit neurons hypo(dys)function hypothesis of, 857
magnetic resonance imaging in, 753
maladaptive anticipatory saccades in, 779
meta-chlorophenylpiperazine challenge test in, 770
methamphetamine psychosis similarity to, 726
methylphenidate effects on, 459
midlatency auditory evoked responses in, 430
mismatch negativity in, 1059
movement disorders in, 1182
natural killer cell activity in, 1131
negative symptoms of, 321-ed, 1182
neurocognition in, 305
neuroleptic depression in, 845-le, 847-le (response)
neurological "hard" signs and family history of psychosis in, 806
NMDA-mediated glutamate release from synaptosomes in, 1191
P300 component abnormalities in, 753
parkinsonism in, 1182
plasma phenylethylamine levels in, 145
platelet membrane lysophosphatidylcholine in, 837
polysomnographic measures in, 904
prenatal maldevelopment of hand ectoderm in, 719
psychiatric symptoms in, 913
REM sleep in, 205
skin conductance orienting response in, 663
among smokers, 107-ed
smooth pursuit eye movement abnormalities in, 537, 753
startle response in, 557

subtype diagnosis in, 63
tardive dyskinesia in, 587, 1182
three-year follow-up of, 913
ventricular-brain ratio in, 887, 913
Schizotypy
impaired neuropsychological functioning in, 424
Scopolamine
memory and P300 latency affected by, 953
mood and sleep in depressed alcoholic patients affected by, 157
REM sleep inhibited by, 151, 157
Seasonal affective disorder (SAD)
phototherapy against, 257
Seasonality
in suicidal behavior, 190 (comment)
Second messenger-generating systems
inositol phospholipid, in manic depressive disorder, 443
Seizures
alpha-1-acid glycoprotein concentrations during, 116
water intoxication and, 417
Self-rating scales
phototherapy against nonseasonal depression assessed via, 257
Senile dementia
of Alzheimer's type, blood glucose and insulin response in, 507
Senile plaques
in Alzheimer's disease, 92
in Down's syndrome, 92
Sensorimotor gating
in rats, NMDA antagonist inhibition of, 557
Serine
metabolism, changes in by serum factor present in psychosis, 966
Serine hydroxymethyltransferase
specific activity of in fibroblasts, 966
Serotonergic diet
against aggression, 88
Serotonin (5-HT), 190
in alcoholism, 1017
in autism, 121
blockers, against chronic schizophrenia, 523
Ca^{2+} response of blood platelets stimulated by, in depression, 310
in mania, 421
memory and, 1075
meta-chlorophenylpiperazine as probe of function of, 1139
in obsessive-compulsive disorder, 131, 467
in panic disorder, 973
platelet uptake, tianeptine effect on in depression, 609
response, following 5,7-dihydroxytryptamine raphe lesions in animal model of depression, 317
reuptake inhibitor, effect of on noradrenergic mediated growth hormone release, 377
reuptake inhibitor, against Alzheimer's disease behavioral symptoms, 140
in schizophrenia, 770
in suicidal behavior, 190 (comment)
Setoperone
against schizophrenia, 771
Setraline
neuroendocrine responses to in alcoholism, 1017
Sexual function
male, aging and sleep disorders correlated with, 1-ed, 15
Skin conductance orienting response
in mental illness, 663
Sleep
EEG, after amitriptyline treatment for depression, 691
EEG, in schizophrenia, 904
onset, cortisol levels at in adolescents with major depression, 25
onset REM periods, in major depression, 1199
paralysis, in narcolepsy, 830
partial deprivation of, against major depression, 817
in schizophrenia, 205, 904
scopolamine effect on, 157
sexual function in elderly men and, 1-ed, 15
stage 3-4, in war-related posttraumatic stress disorder, 618
time, in chronic insomnia, 371
Sleepiness
excessive daytime, in narcolepsy, 830
Smooth pursuit eye-tracking performance
in schizophrenia, 537, 753
Sodium lactate infusion
hypertonic, panic induced by in panic disorder, 628
Somatostatin (SRIF)
in hypothalamic pituitary function, 502
Somnabulism-like behaviors
nocturnal, in elderly people, 4
Spectrin-actin cytoskeleton
in bipolar disorders, 1071-ed
Sphingomyelinase
fibroblast activity of, psychoactive drug effect

on, 841
Spondylitis tuberculosa
manic depressive disorder accompanied by, 526-le
Springtime
greatest frequency of completed suicides during, 190 (comment)
Startle
prepulse inhibition of, haloperidol failure to block effects of phencyclidine and dizocilpine on, 557
Sternberg memory scanning task
response bias during propranolol therapy assessed via, 739
Structured Interview for Schizotypy
parameters of, 424
Stupor
in lethal catatonia, 197
Suicidal behavior
cortisol levels correlated with, 25
fluoxetine-induced, 190 (comment)
seasonality of, 190 (comment)
Sulfatoxy melatonin (aMT6s)
urinary levels of, in anorexia nervosa, 216
Sulpiride
withdrawal from, 528-le
Superior olivary nucleus
activation of by electroconvulsive therapy, 269
Superoxide dismutase (SOD)
in schizophrenia, 409
Sydenham's chorea
obsessive-compulsive disorder symptoms with, 226
Synaptosomes
of schizophrenics, deficient NMDA-mediated glutamate release from, 1191

Tachycardia
in lethal catatonia, 197
Tactile startle
prepulse inhibition of, haloperidol failure to block effects of phencyclidine and dizocilpine on, 557
Tardive dyskinesia
handedness in, 327
manual dominance patterns in, 483
in schizophrenia, 587, 913, 1182
among smokers, 107-ed, 109
Temporal lobes
in bipolar depression, 210
in epilepsy, 1205
in schizophrenia, 753
slowed EEG activity in, in persistently violent psychiatric inpatients, 363
Testosterone
levels, dichotic listening scores correlated with, 704
Tetrahydroaminoacridine (THA)
effect of on P300 in Alzheimer's disease, 953
Thalamus
^{3}H-mepyramine binding in, 349
in schizophrenia, 383, 430
Thiothixene
against schizophrenia, 905, 927
Third ventricle
in schizophrenia, 753
Thrombin
Ca^{2+} response stimulated by, in depression, 310
Thyroid axis
in dysthymic disorder, 283
Thyroid hormone (TH)
treatment, combined with electroconvulsive therapy, against depression, 623
Thyroid-stimulating hormone (TSH)
in major depression and Alzheimer's disease, 567
Thyrotropin-releasing hormone (TRH)
prolactin response to, in depression, 313
stimulation test, in Alzheimer's disease and major depression, 567
Tianeptine
effect of on serotonin platelet uptake in depression, 609
T lymphocytes
in depression, 577
in schizophrenia, 201
Tonic phenomena
reduced, in induction of somnabulism-like behaviors, 4
Tourette's disease
obsessive-compulsive disorder symptoms with, 226
Tranylcypromine
effect of on β-adrenoreceptors, 1122
Trazodone
against Alzheimer's disease behavioral symptoms, 140
Tremors
in lethal catatonia, 197
Triazolam
platelet ^{3}H-imipramine and ^{3}H-paroxetine binding during treatment with, 1056
Tricyclic antidepressants
effect of on β-adrenoreceptors, 1122

alpha-1-acid glycoprotein binding to, 116
against obsessive-compulsive disorder, 225
against panic disorder, 49
sphingomyelinase fibroblast activity and, 841
Trifluoperazine
^{19}F nuclear magnetic resonance spectroscopy of, in rat brain, 656
Trihexyphenydil
effect of on polysomnographic measures in schizophrenia, 905
Triprolidine
^{3}H-mepyramine binding inhibited by, 349
Tryptophan
levels, in alcoholism, 1018
Twin studies
of schizophrenia, 719, 806
Tyrosine hydroxylase
autoreceptor role of midbrain D_2 receptors and, 985
competitive inhibition of, 413

Ulcerative colitis
alpha-1-acid glycoprotein levels in, 117
psychoactive drug binding in, 117
Unpleasant memory
enhanced retrieval of in helpless rats, 493

Vasoactive intestinal peptide (VIP)
in Alzheimer's disease, 81
Ventricle-to-brain ratio
in elderly depressives, 452
in schizophrenia, 887, 913
in tardive dyskinesia, 587
Verapamil
lithium combined with, neurotoxicity of, 635-le
Vestibular nucleus
activation of by electroconvulsive therapy, 269
Violent behavior
persistent, lateralized abnormality of EEG in cases of, 363
Visual Analogue Scale
phototherapy against nonseasonal depression assessed via, 257
Visually guided saccade-maladaptive anticipatory saccade task
schizophrenia assessed via, 780
Vomiting
effects of on hormonal circadian patterns, 37

Water intoxication
in chronic psychosis, demeclocycline against, 417
Wechsler Intelligence Scales
children at risk for schizophrenia assessed via, 177
Wisconsin Card Sorting Test
mood state assessed via, 63, 424, 1205

Zimelidine
dopamine blocking activity of, 226
neuroendocrine responses to in alcoholism, 1017